Retrospective Clinical Investigation into the Association Between Abnormal Blood Clotting, Oral Anticoagulant Therapy, and Medium-Term Mortality in a Cohort of COVID-19 Patients

Biomedicines, Journal Year: 2025, Volume and Issue: 13(3), P. 535 - 535

Published: Feb. 20, 2025

Background/Objectives: People affected by COVID-19 are exposed to abnormal clotting and endothelial dysfunction, which may trigger thromboembolic events. This study aimed at retrospectively investigating whether oral anticoagulant therapy (OAT), encompassing either direct anticoagulants (DOACs), mainly apixaban, or the vitamin K antagonist (VKA) warfarin, could have impacted medium-term mortality in a cohort of SARS-CoV-2 patients. Methods: Among 1238 patients, hospitalized from 17 March 2020 15 June 2021, 247 survivors deceased within 90 days hospitalization were matched 1:1 based on age, sex, intensive care unit (ICU) admission three days. Conditional logistic regression was used estimate associations means odds ratio (OR) with 95% confidence interval (CI). Results: A univariate analysis suggested that OAT, no differently subcutaneous low-molecular-weight heparins (LMWHs) during hospitalization, has significant impact (p value > 0.05) mortality. multivariate analysis, limited baseline variables (i.e., comorbidities pharmacotherapies hospital admission) showing association < revealed that, compared patients living had cancer histories (OR 1.75, CI 1.06–2.90, p = 0.029) suffered asthma 2.25, 1.13–4.47, 0.021). In contrast, heart failure (HF), atrial fibrillation (AF), arteriopathy, chronic obstructive pulmonary disease (COPD), kidney (KF), which, found be associated endpoint 0.05), lost significance analysis. Therapy aldosterone antagonists also appeared 2.49, 1.52–4.08, 0.001); whereas, D supplementation beneficial. Although not conclusive, search into Eudravigilance database, combined consulting digital predictive platform (PLATO, polypharmacology prediction), potential off-target activities, might contribute increasing severity infection. Conclusions: retrospective clinical furnished evidences other pharmacological treatments course.

Language: Английский

---

Long-Term Effects of COVID-19 on Cardiovascular System and the Risk Markers: A Systematic Review

SN Comprehensive Clinical Medicine, Journal Year: 2025, Volume and Issue: 7(1)

Published: Feb. 22, 2025

Language: Английский

---

Long COVID management: a mini review of current recommendations and underutilized modalities

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: June 14, 2024

Long COVID is a condition that develops in subset of patients after COVID-19 infection comprising symptoms varying severity encompassing multiple organ systems. Currently, long without consensus on formal definition, identifiable biomarkers, and validated treatment. expected to be long-term chronic for associated with suffering incapacity. There an urgent need clear management guidelines the primary care provider, who essential bridging gap more specialized improve quality life functionality their living COVID. The purpose this mini review provide providers latest highlights from existing literature regarding most common current recommendations. This also underutilized interventions stellate ganglion blocks low-dose naltrexone, both well-established safety profiles demonstrated some COVID, encourages prompt referral interventional pain management.

Language: Английский

---

CUPID: a free drug discovery platform for the explainable multi-ion channel assessment of cardiotoxicity

European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 117575 - 117575

Published: March 1, 2025

Language: Английский

---